Keratoconus progression in patients with allergy and elevated surface matrix metalloproteinase 9 point-of-care test
Session Details
Session Title: Medical Cornea & Biomechanics
Session Date/Time: Sunday 23/09/2018 | 08:00-10:00
Paper Time: 09:36
Venue: Room A3, Podium 3
First Author: : S.Bagaglia ITALY
Co Author(s): : C. Mazzotta
Abstract Details
Purpose:
To asses Keratoconus (KC) progression in patients with allergies who also tested positive to surface matrix metalloproteinase 9 (MMP-9) point-of-care test.
Setting:
Opthalmology Unit, University of Siena, Viale Mario Bracci , Siena, ITALY
Siena Cross Linking Center, ITALY
Methods:
Methods: Prospective comparative study including 100 stage I-II keratoconic patients, mean age 16.7 ± 4.6 years. All patients underwent an anamnestic questionnaire for concomitant allergic diseases and were screened with the MMP-9 point-of-care test. Patients were divided into 2 groups: KC patients with allergies (KC AL) and KC patients without allergies (KC NAL). Severity of allergy was established by papillary sub-tarsal response grade (PSR) and keratoconus progression assessed by Scheimpflug corneal tomography, corrected distance visual acuity (CDVA) measurement in a 12-month follow-up.
Results:
KC AL group included 52 patients and KC NAL group 48. In the KC AL group 42/52 of patients (81%) were positive to MMP-9 test vs 2 patients in the KC NAL group (4%). The KC AL group showed a statistically significant decrease of average CDVA, from 0.155±0.11 to 0.301±0.2 logMAR (p <0.005) at 12 months; K max value increased significantly, from 50.2 D ±2.7 to 55.2 D ±1.9. KC NAL group revealed keratoconus progression without statistically significant changes. Pearson’s correlation test showed high correlation between K max worsening and severity of PRG in the KC AL group
Conclusions:
The study demonstrated a statistically significant progression of KC in patients with concomitant allergies, positive to MMP-9 point-of-care test vs negative. A high correlation between severity of allergy and keratoconus progression was documented.
Financial Disclosure:
-